Cited by 290Multiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersPolyomavirus and related diseases

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis

Open access

Damato, Valentina, Evoli, Amelia, Iorio, Raffaele·2016·JAMA Neurology

DOI 10.1001/jamaneurol.2016.1637

Open this paper in CoChat — free account Open PDF

Abstract

IMPORTANCE: Neuromyelitis optica spectrum disorders (NMOSDs) are autoimmune astrocytopathies characterized by predominant involvement of the optic nerves and spinal cord. In most patients, an IgG autoantibody binding to astrocytic aquaporin 4, the principal water channel of the central nervous system, is detected. Rituximab, a chimeric monoclonal antibody specific for the CD20 B-lymphocyte surface antigen, has been increasingly adopted as a first-line off-label treatment for patients with NMOSDs. OBJECTIVE: To perform a systematic review and a meta-analysis of the efficacy and safety of rituximab use in NMOSDs, considering the potential predictive factors related to patient response to rituximab in this disease. EVIDENCE REVIEW: English-language studies published between January 1, 2000, and July 31, 2015, were searched in the MEDLINE, Central Register of Controlled Trials (CENTRAL), and clinicaltrials.gov databases. Patient characteristics, outcome measures, treatment regimens, and recorded adverse effects were extracted. FINDINGS: Forty-six studies were included in the systematic review. Twenty-five studies that included 2 or more patients with NMOSDs treated with rituximab were included in the meta-analysis. Differences in the annualized relapse rate ratio and Expanded Disability Status Scale score before and after rituximab therapy were the main efficacy measures. Safety outcomes included the proportion of deaths, withdrawals because of toxic effects, and adverse effects. RESULTS: Among 46 studies involving 438 patients (381 female and 56 male [sex was not specified in 1 patient]; mean age at the outset of treatment, 32 years [age range, 2-77 years]), rituximab therapy resulted in a mean (SE) 0.79 (0.15) (95% CI, -1.08 to -0.49) reduction in the mean annualized relapse rate ratio and a mean (SE) 0.64 (0.27) (95% CI, -1.18 to -0.10) reduction in the mean Expanded Disability Status Scale score. A significant correlation was observed between disease duration and the Expanded Disability Status Scale score. Adverse effects were recorded in 114 of 438 (26%) patients treated with rituximab. Specifically, 45 patients (10.3%) experienced infusion-related adverse effects, 40 patients (9.1%) had an infection, 20 patients (4.6%) developed persistent leukopenia, 2 patients (0.5%) were diagnosed as having posterior reversible encephalopathy, and 7 patients (1.6%) died. CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis provides evidence that rituximab therapy reduces the frequency of NMOSD relapses and neurological disability in patients with NMOSDs. However, the safety profile suggests caution in prescribing rituximab as a first-line therapy.

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2016.1637

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S., & Hinson, S. R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050304 · Cited by 2,288
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,182
An open label study of the effects of rituximab in neuromyelitis optica
Cree, B., Lamb, S., Morgan, K., Chen, A., Waubant, E. L., & Genain, C. P. (2005) · Neurology · doi:10.1212/01.wnl.0000159399.81861.d5 · Cited by 646
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis
Weinshenker, B. G., Wingerchuk, D. M., Vukusic, S., Linbo, L., Pittock, S. J., Lucchinetti, C. F., & Lennon, V. A. (2006) · Annals of Neurology · doi:10.1002/ana.20770 · Cited by 585
Treatment of Neuromyelitis Optica With Rituximab
Jacob, A., Weinshenker, B. G., Violich, I., McLinskey, N., Krupp, L., Fox, R. J., Wingerchuk, D. M., Boggild, M., Constantinescu, C. S., Miller, A., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.noc80069 · Cited by 460
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica
Jarius, S., Aboul‐Enein, F., Waters, P. J., Kuenz, B., Hauser, A., Berger, T., Lang, W., Reindl, M., Vincent, A. C., & Kristoferitsch, W. (2008) · Brain · doi:10.1093/brain/awn240 · Cited by 433
NMO-IgG predicts the outcome of recurrent optic neuritis
Matiello, M., Lennon, V. A., Jacob, A., Pittock, S. J., Lucchinetti, C. F., Wingerchuk, D. M., & Weinshenker, B. G. (2008) · Neurology · doi:10.1212/01.wnl.0000303817.82134.da · Cited by 364
Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease
Dale, R. C., Brilot, F., Duffy, L. V., Twilt, M., Waldman, A. T., Narula, S., Muscal, E., Deiva, K., Andersen, E., Eyre, M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000570 · Cited by 347

Flagged first, then by citations

Show all 66 references

Sorted by citations

Items 201–290 of 290

Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study.
Ahadi, M. S., Sahraian, M. A., Shaygannejad, V., Anjidani, N., Nejad, S. E. M., Moghadam, N. B., Ayromlou, H., Pour, G. A. Y., Yazdanbakhsh, S., Jafari, M., et al. (2021) · Europe PMC (PubMed Central) · doi:10.22088/cjim.12.0.491 · Cited by 4
“Novel therapeutics targeting CD20+ B cells are increasingly incorporated in NMOSD due to considerable annualized relapse rate reduction and disability improvement (2, 3).”
Background
Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder
Gómez‐Figueroa, E., Noriega-Morales, G., Vanegas, A. C., Zabala‐Ángeles, I., García‐Estrada, C., Neri, D., de Saráchaga, A. J., Rivas‐Alonso, V., Corona, T., & Flores-Rivera, J. D. J. (2020) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2020.106007 · Cited by 4
Comparison of treatment efficacy and cost-effectiveness of rituximab and oral agents among patients with neuromyelitis optica spectrum disorders: a population-based cohort study
Lee, H. L., Kang, M., Seok, J. M., Kim, B., & Kim, B. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251314020 · Cited by 3
Relapses during treatment with monoclonal antibodies targeting B-cells in NMOSD
Cao, S., Zhou, X., Du, J., Zhang, J., Zhu, Y., Wei, L., Xia, M., Li, Q., Xu, Y., Xue, Q., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13118-9 · Cited by 3
Risk factors and clinical consequences of rituximab infusion-related reactions
Hou, C.-H., Chang, H., Ong, Y.-C., Kuo, M.-C., Kao, H., & Lee, H.-L. (2025) · Medicine · doi:10.1097/md.0000000000042972 · Cited by 3
Consensus recommendations for the diagnosis and management of neuromyelitis optica spectrum disorder: A Saudi expert panel review
Aljarallah, S., Althobaiti, A., Abulaban, A. A., Aldosari, F. M., Alhasan, S., Ali, E. N., Alnajashi, H. A., Mutlaq, A. A., Althubaiti, I. A., Alyafeai, R., et al. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106847 · Cited by 4
A real-world comparative study on the efficacy and safety of tocilizumab and rituximab in patients with neuromyelitis optica spectrum disease and myelin oligodendrocyte glycoprotein antibody-associated disease
Shi, Y., Li, Y., Xu, X., Liu, J., An, X., Zhang, M., Shen, Y., Pan, J., Jia, D., & Zhang, C. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106871 · Cited by 3
Role of B cells and pathogenic autoantibodies in autoimmune CNS and PNS neurologic diseases
Stathopoulos, P., & Dalakas, M. C. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90887-0.00003-1 · Cited by 5
Genetic Insights into Therapeutic Targets for Neuromyelitis Optica Spectrum Disorders: A Mendelian Randomization Study
Cao, Y., Zhang, J., & Wang, J. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04612-8 · Cited by 4
Real World Effectiveness and Tolerability of Novel Monoclonal Antibodies and Rituximab for NMOSD
Javed, Z., Du, M., Rensel, M. R., Hua, L. H., Hersh, C. M., Abbatemarco, J., Conway, D. S., Ontaneda, D., Cohen, J. A., & Kunchok, A. C. (2025) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70160 · Cited by 3
“Although multiple studies have demonstrated the safety and efficacy of rituximab in the majority of NMOSD patients, there are a few patients who fail treatment, possibly due to genotypic variability or the development of immunogenicity, who may benefit from nMAb treat-ment [8, 18, 19].”
Rituximab in Neuromyelitis Optica Spectrum Disorders
Kim, S., & Kim, H. J. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.5933 · Cited by 3
Increased proportion of CD20+ T cells after rituximab treatment in patient with neuromyelitis optica later diagnosed with lung B-cell lymphoma: A case report
Lee, J. K., Kwon, S., Han, J., Yoon, S. E., Kim, B. J., & Kang, E. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577564 · Cited by 3
Anti-B-cell therapy in patients with neuromyelitis optica spectrum disorders
Kotov, S. V., Novikova, E. S., & Котов, А. С. (2021) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2021-4-18-24 · Cited by 3
Therapie antikörpervermittelter Enzephalomyelitiden
Ayzenberg, I., & Kleiter, I. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01090-4 · Cited by 3
Pathogenesis of tissue injury in the brain in patients with systemic lupus erythematosus
Hunt, D. P. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814551-7.00038-6 · Cited by 3
Detrimental roles of innate immune cells in neuromyelitis optica spectrum disorder: Pathogenesis and therapeutic targeting
Loh, K. M., Cheok, Y. Y., Tang, T. F., Looi, C. Y., Wong, W. F., & Abdullah, S. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf068 · Cited by 2
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Mechanisms, Syndromes, and Management
Dolan, R. F., Rangu, N., Dang, D. H., & Melson, A. T. (2025) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000597 · Cited by 2
Updates on the Acute and Maintenance Management of Optic Neuritis Including Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody Disease
Alchaki, A. R. (2026) · Neurologic Clinics · doi:10.1016/j.ncl.2025.12.003 · Cited by 2
CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy
Wen, M., Zheng, R., Zhang, H., Goldberg, S. Y., Jian, Z., Gao, Y., Cheng, R., Wen, L., Zhao, Y. Y., Kenderian, S. S., et al. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03662-6 · Cited by 2
Neurologic autoimmune diseases
Rodríguez, Y., Restrepo, L., Chang, C. C.-C., & Anaya, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95061-9.00033-3 · Cited by 2
Rituximab Therapy for Immune-Mediated Neurological Diseases: Our Experience at a Tertiary Care Centre
Khandait, P. D., Rohatgi, S. J., Nirhale, S. P., Rao, P., & Naphade, P. U. (2024) · Cureus · doi:10.7759/cureus.62227 · Cited by 2
Current treatment and management of neuromyelitis optica spectrum disorder: areas for improvement
Jahani, S., Rezaeimanesh, N., Owji, M., Bafrani, M. A., Lapevandani, M. M., & Moghadasi, A. N. (2025) · Expert Review of Ophthalmology · doi:10.1080/17469899.2025.2489737 · Cited by 2
“Although there were no differences in the EDSS, an interesting trial showed that patients on rituximab had a 0% recurrence rate compared to 37% on placebo [35,36].”
Autoimmune neuro-ophthalmic disorders: pathophysiologic mechanisms and targeted biologic therapies
Rowe, L. W., Barry, Z. R., Mackay, D. D., Lai, K. E., & Ciulla, T. A. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2491603 · Cited by 2
“Although not FDA approved, rituximab has demonstrated efficacy and promise when used off-label for the management of NMOSD [114,115], MOGAD [116–118], and MS [119–121].”
A comparative study on clinico-radiological profile, treatment responses and outcomes of double seronegative NMOSD compared to AQP4-IgG positive NMOSD, and MOGAD
Lotlikar, R. S., Nair, S. S., Prasad, A. K., Narasimhaiah, D., Thomas, B., & Sundaram, S. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106669 · Cited by 2
Seronegative neuromyelitis optica spectrum disorder: severe polysymptomatic presentation with successful treatment response
da Rosa, G. P., Costa, F., Guimarães, J., & Friões, F. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-228553 · Cited by 2
Randomized Controlled Trials for Neuromyelitis Optica Spectrum Disorder
Cabal-Herrera, A. M., & Mateen, F. J. (2021) · The Neurologist · doi:10.1097/nrl.0000000000000376 · Cited by 2
A Race to the Finish
Pryor, K. P., Weber, B., Reilly, C. R., Sun, Y., & Loscalzo, J. (2023) · New England Journal of Medicine · doi:10.1056/nejmcps2305278 · Cited by 2
Editorial: Next generation B cell targeting therapies in autoimmune diseases
Li, R., Zhu, J., Wang, S., Zhang, B., Tian, L., & Fu, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1322546 · Cited by 2
Neurologic and Psychiatric Effects of Cytokines and Targeted Biological Therapies
Beckwith, N., & Helfgott, S. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-16928-2_29 · Cited by 1
CRION: Need for a consensus for long term management
Mushtaq, F., Ansari, F. A., Awan, M. A., Chaudhry, B. Z., Ullah, Z., & Ahmad, A. (2021) · Neuroimmunology Reports · doi:10.1016/j.nerep.2021.100046 · Cited by 1
Very late-onset neuromyelitis optica presenting with simultaneous bilateral optic neuritis and myelitis: A case report
Gandelman, S., Parauda, S. C., & Dohle, C. (2024) · Neuroimmunology Reports · doi:10.1016/j.nerep.2024.100227 · Cited by 1
Shared mechanisms in neuromyelitis optica spectrum disorder and spaceflight-associated neuro-ocular syndrome: Insights into central nervous system fluid dynamics, glymphatic function, and astrocyte dysregulation
Paladugu, P., Kumar, R., Sporn, K., Ong, J., Song, A., Sekhar, T. C., Gowda, C., Davidoff, N., Shin, S. D., & Lee, A. G. (2025) · Life Sciences in Space Research · doi:10.1016/j.lssr.2025.05.006 · Cited by 3
The real-world experience of biologics for neuromyelitis optica spectrum disorders as first-line and switched therapy
Matsuyoshi, A., Shinoda, K., Takeuchi, H., Mizutani, K., Kira, Y., Iwao, K., Watanabe, M., Masaki, K., & Isobe, N. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578799 · Cited by 1
Relapse-related outcomes in the Danish population-based AQP4- antibody seropositive neuromyelitis optica spectrum disorder cohort
Mamoei, S., Möller, S., Magyari, M., Sellebjerg, F. T., Frederiksen, J. L., Svendsen, K. B., Saleem, R., Søndergaard, H. B., Nilsson, A. C., Papp, V., et al. (2026) · Neurological Sciences · doi:10.1007/s10072-025-08754-y · Cited by 1
Real-World Multicenter Cohort Study of Inebilizumab vs Low-Dose Rituximab in Neuromyelitis Optica Spectrum Disorders
Xu, Q., Zhang, L., Duan, X., Zhou, K., Li, Z., Yang, X. L., Wang, J., Jiang, J., Xu, K., Yu, G., et al. (2026) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200586 · Cited by 1
Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial
Wu, L., Wei, M., Gao, F., Zhang, H., Wang, J., Xiang, F., Gao, S., Liu, R., Yin, J., Guo, Y., et al. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-00960-w · Cited by 1
“The available antibodies include eculizumab (anti-C5) [15], ravulizumab (anti-C5) [16], satralizumab (anti-interleukin (IL)-6 receptor) [17], inebilizumab (anti-CD19) [18], and rituximab (anti-CD20) [19].”
Unmet needs in the care of patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody associated disease: insights from Germany
Giglhuber, K., Bertrand, A., Zappe, C., Kleiter, I., Ayzenberg, I., Berthele, A., & the Neuromyelitis Optica Study Group (NEMOS)§ (2026) · Neurological Research and Practice · doi:10.1186/s42466-026-00503-6 · Cited by 1
“This is unsurprising, as it aligns with earlier as well as recent analyses of the NEMOS registry data, and implicitly validates the efficacy and safety of this off-label drug over a period of around two decades [30–34].”
Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial
Wu, L., 顾亮亮, Fan, W., Wei, M., Dai, T., Li, X., Xiao, L., Li, B., Tian, D., Duan, R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04583-4 · Cited by 1
Rituximab associated necrosis: A case report
Ashtari, F., Hakamifard, A., Hariri, A., & Gholipourshahraki, T. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.101429 · Cited by 1
Autoimmune Demyelinating Syndromes: Aquaporin-4-IgG-positive NMOSD and MOG - IgG Associated Disorder
Sechi, E., & Flanagan, E. P. (2021) · Springer eBooks · doi:10.1007/978-3-030-61883-4_15 · Cited by 1
Possibilities of therapy for neuromyelitis optica spectrum disorders
Novikova, E. S. (2022) · Russian Journal of Child Neurology · doi:10.17650/2073-8803-2021-16-4-49-58 · Cited by 1
Microorganisms in Pathogenesis and Management of Neuromyelitis Optica Spectrum Disorder
Moghadasi, A. N., & Rezaeimanesh, N. (2022) · Springer eBooks · doi:10.1007/978-981-19-4800-8_10 · Cited by 1
Are monoclonals the only panacea for treatment of aquaporin-4 positive NMOSD? Experience from a low-&middle-income (LMIC) region
Dhamija, K., Manjappaiah, M. G., Thennarasu, K., Mahadevan, A., & Netravathi, M. (2024) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2024.108212 · Cited by 1
Long-term efficacy and safety of low-dose rituximab strategy in neuromyelitis optica spectrum disorder: a retrospective cohort study on treatment compliance and clinical outcomes
Wang, Y., Zhao, C., Pan, Z., Zhang, R., Li, Y., Li, H., Zhao, D., & Guo, J. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03770-9 · Cited by 1
Isolated recurrent myelitis in a 7-year-old child with serum aquaporin-4 IgG antibodies
Bianchi, A., Bartolini, E., Melani, F., Guerrini, R., & Mascalchi, M. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8332-8 · Cited by 1
Rituximab in Neuromyelitis Optica Spectrum Disorders—Reply
Damato, V., Evoli, A., & Iorio, R. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.5936 · Cited by 1
Self-citation
Perfil de pacientes com neuromielite óptica em tratamento com rituximabe
Júnior, I. A. D. S., Dourado, C. A. R. D. O., & dos Santos, M. I. (2020) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e3953.2020 · Cited by 1
Clinical Approach to Stiff Person Syndrome
Galli, J. R., & Clardy, S. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-61883-4_30 · Cited by 1
Seeking transpaRINcy for rituximab dosing in NMOSD
Clarke, A. J., Prosser, J., & Badve, M. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30280-5 · Cited by 1
Rituximab reduziert Schübe und Behinderung
Menge, T. (2017) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-017-2095-3
Maladies du spectre NMO
Marignier, R. (2018) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2018.01.010
Clinical commentary on ‘Late-onset neutropenia and neurological relapse during long-term rituximab therapy in MOG antibody spectrum disorder’
Hacohen, Y., & Brownlee, W. J. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518775245
Was kann die Antikörpertherapie in der Neurologie?
Meuth, S. G., & Pawlitzki, M. (2019) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-019-2169-9
Monoclonal Antibody Therapy for Neuromyelitis Optica: A Systematic Review and Meta-Analysis
Caranfa, J. T., Kohn, C. G., Wl, B., & Waitzman, D. M. (2019) · Neurological Disorders
The nervous system in systemic lupus erythematosus
Hunt, D. P. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814551-7.00049-0
Advances in the Treatment of Neuromyelitis Optica Spectrum Disorders
Brandstadter, R., & Bar‐Or, A. (2020) · touchREVIEWS in Neurology · doi:10.17925/usn.2020.16.1.38
Health inequalities and disabled people in South Korea: A mixed-method analysis
Lee, H. (2020) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Neuromyelitis Optica Spectrum Disorders and Glial Fibrillary Acidic Protein Autoimmunity
Dalmau, J. O., & Graus, F. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108696722.012
Contemporary views on disorders of neuromiyelitis optica spectrum. Clinical case from personal practice
Шкробот, С. І., Бударна, О. Ю., Duve, K. V., Ткачук, Н. І., & Milevska-Vovchyk, L. (2021) · Ukrains kyi Visnyk Psykhonevrolohii · doi:10.36927/2079-0325-v29-is2-2021-15
Effectiveness and Safety of Immunosuppressive Drug Therapy for Neuromyelitis Optica Spectrum Disorders: An Overview of Meta-Analyses and Systematic Reviews
Luo, Y., Deng, Y., Ran, H., Yu, L., Ma, C., Zhao, L., & Li, Y. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220922151442
“The earlier treatment may reduce disability more effectively [17, 26].”
BackgroundResult
The Neuroprotective Mechanism of IGF-2 in Neuromyelitis optica spectrum disorderPreprint
Zhang, Y., Xu, N., Yu, K., Wang, X., Gu, J., Yu, L., An, J., Wang, Y., Dong, M., Sun, C., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2542972/v1
Gestione delle bioterapie ad uso dei neurologi
Collongues, N., Felten, R., Seze, J. D., & Bigaut, K. (2023) · EMC - Neurologia · doi:10.1016/s1634-7072(23)47683-0
Update NMOSD
Giglhuber, K., Kümpfel, T., & Berthele, A. (2023) · DNP – Die Neurologie & Psychiatrie · doi:10.1007/s15202-023-5689-2
Evolución clínica en neuromielitis óptica comparando el manejo con azatioprina o rituximab
Botero, P. S., Laverde, T. G., Vallejo-Tamayo, S., Castro, I. T., Villada, N. R., Restrepo, C. A., & Rodas, M. I. Z. (2023) · Acta neurológica colombiana · doi:10.22379/anc.v39i1.882
An overview of neuromyelitis optica spectrum disorders
Srivastava, S., Tolaymat, S., Sharma, K., Sriwastava, S., & Bernitsas, E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95343-6.00008-x · Cited by 1
Can quantitative monitoring of B cells evaluate the efficacy of Rituximab in primary CNS demyelinating disorders?
Chatterjee, S., Sarkar, P., Chatterjee, M., & Ray, B. K. (2024) · Annals of Medical Science and Research · doi:10.4103/amsr.amsr_36_23
New treatment options for Neuromyelitis optica spectrum disorders (NMOSD)
Szilasiová, J. (2024) · Neurologie pro praxi · doi:10.36290/neu.2024.025
Neuromyelitis optica spectrum disorder and other central nervous system inflammatory diseases
Thakolwiboon, S., & Flanagan, E. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00019-9
Significance of Autoantibodies
Hampe, C. S. (2024) · Springer eBooks · doi:10.1007/978-3-031-24297-7_4-1
Neue Therapieoptionen bei Neuromyelitis- optica-Spektrum-Erkrankung
Konitsioti, A., Laurent, S. A., Fink, G. R., & Warnke, C. (2024) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-024-4013-9
Steroids and Immunomodulating Agents
Alcoba, S., & Perez, D. (2024) · Springer eBooks · doi:10.1007/978-3-031-62224-3_19
Significance of Autoantibodies
Hampe, C. S. (2024) · Springer eBooks · doi:10.1007/978-3-031-60006-7_4
Concurrent myasthenia gravis and neuromyelitis optica spectrum disorder: a rare intersection of autoimmune pathologies
Tunç, A., Elci, O. U., Akbaş, A. A., & Öncel, S. (2025) · BMJ Case Reports · doi:10.1136/bcr-2024-263081
“11 Furthermore, the differential response of MuSK-MG patients to rituximab compared with AChR patients with MG accentuates the need to understand the distinct immunopathologies of MG subtypes.”
Neuromyelitis Optica spectrum disorders: Therapeutic considerations
Andabaka, M., Mesaroš, Š., Veselinovic, N. D., Tamaš, O., Budimkic, M. S., & Drulovic, J. S. (2025) · Medicinska istrazivanja · doi:10.5937/medi58-55665
Efficacy of a fixed-interval, body surface area-adjusted rituximab regimen in Singaporean patients with CNS inflammatory demyelinating diseases
Tan, J. M. M., SIVALINGAM, T., Wong, D. Y. J., Tye, J. S. N., Aw, A. Y. Y., Siew, R. W. E., Peng, X., Tan, K., Saffari, S. E., & Yeo, T. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106924
The impact of physical and psychological health outcomes on stigma in people with neuromyelitis optica spectrum disorder: A cross-sectional study
Shaygannejad, A., Panah, M. Y., Vaheb, S., Afshari-Safavi, A., Shaygannejad, V., & Mirmosayyeb, O. (2025) · Medicine · doi:10.1097/md.0000000000046738
Additional file 1 of Bruton’s tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder
Liu, Y., Huang, Z., Zhang, T.-X., Han, B., Yang, G., Jia, D., Yang, L., Liu, Q., Lau, A. Y. L., Paul, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26657320
Neurological and paraclinical features differentiating Systemic lupus erythematosus, Sjögren’s disease, and neuromyelitis optica spectrum disorders
Nóbrega, I. L. P., Nascimento, M. M. P., Santiago, I. B., de Carvalho, J. F., Pitombeira, M. S., & Rodrigues, C. E. M. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2026.106972
A real-world study on the long-term efficacy of rituximab in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease
Yu, C., Chen, X., Jiang, W., Sun, H., Gao, S., Huang, D., Wu, L., & Yu, S. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2026.107154
Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disease: A Systematic Review of Pharmacotherapeutic Alternatives, Current Strategies and Prospective Biological Targets
Sanabria‐Castro, A., Reyes, J. D. V., Madrigal‐Gamboa, V., & Chin-Cheng, R. (2026) · Neuroglia · doi:10.3390/neuroglia7020012
Subsequent treatment strategies following rituximab-resistance in AQP4-IgG+ neuromyelitis optica spectrum disorder: a case series
Deng, M., Chen, L., Chen, W., Zeng, K., Yao, Y., Chen, H., & Lin, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1762535
Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4 ‐ IgG ‐Positive NMOSD
Lin, J., Xue, B., Xie, D., Li, J., Pan, J., Zhu, L., Tong, Q., Lin, J., Zhu, R., Zhang, X., et al. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70412
“Observational studies of RTX highlight that earlier initiation associates with reduced long-term disability accumulation [12–14, 26, 27].”
Synergistic Interaction Between MALAT1/miR‐30b‐5p/BAFF Axis and Inflammatory Cytokines Underlies Rituximab‐Refractory NMOSD
Deng, M., Zeng, K., Chen, W., Chen, J., Lin, X., Chen, L., Yao, Y. Q., Chen, H., & Lin, A. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70973
Seltener, sehr später Beginn einer NMO (Neuromyelitis optica)
Maximov, M., & Lago, A. R. (2026) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2878-1828
The nervous system in systemic lupus erythematosus
Bridson, J. D., & Hunt, D. P. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33957-8.00050-0
Neuromyelitis optica spectrum disorder: a 5-year experience in a tertiary hospital in Northern Vietnam
Nguyen, Q. H., Thuy, H. T. T., Nguyen, D. M., Tran, H. H., Le, A. D., & Nguyen, N. H. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2026.107358
French guidelines for the diagnosis and management of neuromyelitis optica spectrum disorder
Giorgi, L., Marignier, R., Pique, J., Maurey, H., Papeix, C., Ciron, J., Collongues, N., Cheuret, E., Zéphir, H., Meyer, P., et al. (2026) · Revue Neurologique · doi:10.1016/j.neurol.2026.06.004
Patient-reported outcomes in Chinese patients with AQP4-IgG–positive neuromyelitis optica spectrum disorder on inebilizumab therapy: a cross-sectional study
Yin, H., Hao, M., & Xu, Y. (2026) · BMC Neurology · doi:10.1186/s12883-026-05163-2
A systematic review and meta-analysis of the efficacy and safety of eculizumab in AQP4-IgG–positive neuromyelitis optica spectrum disorder
Liu, W., Wu, J., Liu, Z., Lu, H., Wen, Q., Li, J., & Lin, F. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2026.107678
Case Report: Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder: Diagnostic Challenges and Transition From B‐Cell Depletion Therapy to Ravulizumab
Zabeti, A. (2026) · Clinical Case Reports · doi:10.1002/ccr3.73704

Authors: Damato, V., Evoli, A., & Iorio, R.
Affiliations: Agostino Gemelli University Polyclinic (IT)
Don Carlo Gnocchi Foundation (IT)
Corresponding author: Iorio, Raffaele
ORCID: Damato, Valentina
Evoli, Amelia
Iorio, Raffaele
Venue: JAMA Neurology
Publisher: American Medical Association (AMA)
Published: 2016-11-01
Volume: 73
Issue: 11
Pages: 1342
ISSN: 2168-6149 (ISSN-L)
DOI: 10.1001/jamaneurol.2016.1637
OpenAlex: W2524675862
Cited by: 290
References: 66
Citations by year: 2026: 21 · 2025: 26 · 2024: 25 · 2023: 29 · 2022: 34 · 2021: 50 · 2020: 49 · 2019: 24 · 2018: 20 · 2017: 11 · 2016: 1
FWCI: 2.93
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA Neurology (publishedVersion)
PubMed (publishedVersion)
Florence Research (University of Florence) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
Keywords: neuromyelitis optica spectrum disorder, rituximab, CD20, off-label drug use, aquaporin-4 antibodies, annualized relapse rate, Expanded Disability Status Scale, disability progression, treatment safety, disease duration, predictors of treatment response, autoimmune demyelinating disease, B-cell depletion therapy, relapse prevention
MeSH terms: Rituximab, Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Immunologic Factors, Male, Middle Aged, Neuromyelitis Optica, Outcome Assessment, Health Care, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks